Skip to main content
SpringerLink
Log in

Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a well recognised form of chronic liver disease that has recently gained greater recognition. Originally described in the late 1950s, NAFLD is currently considered the leading cause of abnormal liver enzyme levels in the US, closely paralleling the increase in obesity and diabetes mellitus. NAFLD has a worldwide distribution, affecting both adults and children, and typically is seen in association with obesity, diabetes, hypertension and hypertriglyceridaemia. Most patients are asymptomatic and usually present with mild elevations in aminotransferases.

The natural history of NAFLD is not clearly defined but progression to cirrhosis and end-stage liver disease is well recognised in some patients. The accumulation of hepatic steatosis is thought to occur initially, primarily through hepatic and peripheral insulin resistance, which leads to altered glucose and free fatty acid metabolism. The progression from simple fatty liver to more severe forms of NAFLD (nonalcoholic steatohepatitis and cirrhosis) is much less clear but evidence suggests that oxidative stress may preferentially enhance proinflammatory cytokines, which leads to cellular adaptations and dysfunction followed by development of inflammation, necrosis and fibrosis.

Therapeutic modalities remain limited and are largely focused on correcting the underlying insulin resistance or reducing oxidative stress. However, at the present time, there are several limitations to the current potential therapies, mainly because of the lack of large-scale, prospective, randomised studies, as well as clearly defined histological endpoints. Ultimately, the future for potential therapeutic modalities to treat this disease are quite promising, but further research is needed to clearly demonstrate which therapy or therapies will be effective at eliminating fatty liver disease and its potential complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Fig. 3
Table III

Similar content being viewed by others

References

  1. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958; 34: 686–93

    PubMed  CAS  Google Scholar 

  2. Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic disease: its similarity to alcoholic hepatic disease. Am J Clin Pathol 1975; 63(3): 318–31

    PubMed  CAS  Google Scholar 

  3. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811–6

    Article  PubMed  CAS  Google Scholar 

  4. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8

    PubMed  CAS  Google Scholar 

  5. Teli MR, James OFW, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714–9

    Article  PubMed  CAS  Google Scholar 

  6. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9

    Article  PubMed  CAS  Google Scholar 

  7. Lee RG. Nonalcoholic steatohepatitis: a study of 39 patients. Hum Pathol 1989; 20: 594–8

    Article  PubMed  CAS  Google Scholar 

  8. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80

    Article  PubMed  Google Scholar 

  9. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103–9

    PubMed  CAS  Google Scholar 

  10. Harrison SA, Torgerson S, Hayashi P. Natural history of NASH: a clinical histopathologic study. Am J Gastroenterol 2003; 98: 2042–7

    Article  PubMed  Google Scholar 

  11. Willner IR, Waters B, Raj Patil S, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957–61

    Article  PubMed  CAS  Google Scholar 

  12. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplant for cryptogenic cirrhosis. Liver Transplant 2001; 7: 363–73

    Article  CAS  Google Scholar 

  13. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797–801

    Article  PubMed  CAS  Google Scholar 

  14. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154–60

    Article  PubMed  Google Scholar 

  15. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40

    Article  PubMed  Google Scholar 

  16. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002; 123: 375–8

    Article  PubMed  Google Scholar 

  17. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635–43

    PubMed  CAS  Google Scholar 

  18. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24: 1936–40

    Article  PubMed  CAS  Google Scholar 

  19. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 1723–7

    Article  PubMed  Google Scholar 

  20. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey 1988–1994. Vol. I. Vital Health Statistics. Hyattsville (MD): National Center for Health Statistics, 1994

    Google Scholar 

  21. Harrison SA, Diehl AM. Fat and the liver: a molecular overview. Semin Gastrointest Dis 2002; 13(1): 3–16

    PubMed  Google Scholar 

  22. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in the general population of Okinowa, Japan. Jpn J Med 1988; 27: 142–9

    Article  PubMed  CAS  Google Scholar 

  23. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study. Hepatology 1994; 20: 1442–9

    Article  PubMed  CAS  Google Scholar 

  24. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649–57

    Article  PubMed  Google Scholar 

  25. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746–52

    Article  PubMed  Google Scholar 

  26. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–10

    Article  PubMed  CAS  Google Scholar 

  27. Garcia-Monson C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716–24

    Article  Google Scholar 

  28. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100

    Article  PubMed  CAS  Google Scholar 

  29. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428–32

    Article  PubMed  CAS  Google Scholar 

  30. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002–9

    Article  PubMed  CAS  Google Scholar 

  31. Manton ND, Lipsett J, Moore DJ, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173: 476–9

    PubMed  CAS  Google Scholar 

  32. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–30

    Article  PubMed  CAS  Google Scholar 

  33. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–45

    PubMed  CAS  Google Scholar 

  34. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117–23

    Article  PubMed  CAS  Google Scholar 

  35. Harrison SA, Hayashi P. Clinical factors associated with fibrosis in 102 patients with nonalcoholic steatohepatitis [abstract]. Hepatology 2002; 36: 412A

    Google Scholar 

  36. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142–9

    Article  PubMed  CAS  Google Scholar 

  37. Santos L, Molina EG, Jeffers L, et al. Prevalence of nonalcoholic steatohepatitis among ethnic groups [abstract]. Gastroenterology 2001; 120: A117

    Google Scholar 

  38. Caldwell SH, Harris DM, Patrie JT, et al. Is NASH underdiagnosed among African-Americans. Am J Gastroenterol 2002; 97: 1496–500

    Article  PubMed  Google Scholar 

  39. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–62

    Article  PubMed  CAS  Google Scholar 

  40. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002; 13: 17–30

    PubMed  Google Scholar 

  41. Reaven G. Syndrome X: 10 years after [discussion appears in Drugs 1999; 58 Suppl. 1: 75–82]. Drugs 1999; 58 Suppl. 1: 19–20

    Article  PubMed  Google Scholar 

  42. DeFronso RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94

    Article  Google Scholar 

  43. Marchesini G, Brizi M, Marsell-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5

    Article  PubMed  CAS  Google Scholar 

  44. Sanyal AJ, Campbell-Sargent C, Mirshani F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183–92

    Article  PubMed  CAS  Google Scholar 

  45. Pagano G, Pacini G, Musso G, et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367–72

    Article  PubMed  CAS  Google Scholar 

  46. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 2002; 35: 373–9

    Article  PubMed  CAS  Google Scholar 

  47. Marceau P, Biron S, Hould FS, et al. Liver pathology and metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–7

    Article  PubMed  CAS  Google Scholar 

  48. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311–8

    Article  PubMed  CAS  Google Scholar 

  49. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421–9

    Article  PubMed  CAS  Google Scholar 

  50. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847–50

    Article  PubMed  CAS  Google Scholar 

  51. Mendler M-H, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155–63

    Article  PubMed  CAS  Google Scholar 

  52. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931–9

    Article  PubMed  CAS  Google Scholar 

  53. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000; 35: 319–24

    Article  PubMed  CAS  Google Scholar 

  54. Saadeh S, Zobair M, Younossi ZM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745–50

    Article  PubMed  Google Scholar 

  55. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 2468–73

    Article  Google Scholar 

  56. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in NASH. J Hepatology 1999; 31: 430–4

    Article  CAS  Google Scholar 

  57. Day C, James O. Steatohepatitis: a tale of two “hits”? [editorial]. Gastroenterology 1998; 114: 842–5

    Article  PubMed  CAS  Google Scholar 

  58. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345–50

    PubMed  CAS  Google Scholar 

  59. Seppala-Lindroos A, Vehkavaara S, Hakkinen A-M, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023–8

    Article  PubMed  CAS  Google Scholar 

  60. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. Clin Endocrinol Metab 2002; 87: 3019–22

    Article  CAS  Google Scholar 

  61. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998; 115: 997–1001

    Article  PubMed  CAS  Google Scholar 

  62. Rutter GA. Diabetes: the importance of the liver. Curr Biol 2000; 10: R736–8

    Article  PubMed  CAS  Google Scholar 

  63. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799–806

    Article  PubMed  CAS  Google Scholar 

  64. Hug C, Lodish HF. Diabetes, obesity and acrp30/adiponectin. Biotechniques 2002; 33: 654–62

    PubMed  CAS  Google Scholar 

  65. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in skeletal muscle. Diabetologia 2000; 43: 677–83

    Article  Google Scholar 

  66. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31

    PubMed  CAS  Google Scholar 

  67. Cummings MH, Watts GF, Umpleby AM, et al. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995; 44: 1059–65

    Article  PubMed  CAS  Google Scholar 

  68. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898–904

    Article  PubMed  CAS  Google Scholar 

  69. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 7522–7

    Article  PubMed  CAS  Google Scholar 

  70. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402–7

    Article  PubMed  CAS  Google Scholar 

  71. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 2001; 293: 1673–7

    Article  PubMed  CAS  Google Scholar 

  72. Mensenkamp AR, van Luyn MJA, van Goor H, et al. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J Hepatol 2000; 33: 189–98

    Article  PubMed  CAS  Google Scholar 

  73. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995–9

    Article  PubMed  CAS  Google Scholar 

  74. Bjorkegren J, Beigneux A, Bergo MO, et al. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002; 277: 5476–83

    Article  PubMed  CAS  Google Scholar 

  75. Ceddia RB, Koistinen HA, Zierath JR, et al. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163–76

    Article  PubMed  CAS  Google Scholar 

  76. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292–5

    Article  PubMed  CAS  Google Scholar 

  77. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584–9

    Article  PubMed  CAS  Google Scholar 

  78. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000; 11: 410–6

    Article  PubMed  CAS  Google Scholar 

  79. Barzilai N, Wang J, Massilon D, et al. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997; 100: 3105–10

    Article  PubMed  CAS  Google Scholar 

  80. Sahu A. Resistance to the satiety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y neurons. J Neuroendocrinol 2002; 14: 796–804

    Article  PubMed  CAS  Google Scholar 

  81. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665–8

    Article  PubMed  CAS  Google Scholar 

  82. Zanger R, Novak R. Effects of fatty acids and ketone bodies on cytochromes p4502B, 4A, 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys 1997; 337: 217–24

    Article  Google Scholar 

  83. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067–75

    Article  PubMed  CAS  Google Scholar 

  84. Weltman MD, Farrell GC, Hall P. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128–33

    Article  PubMed  CAS  Google Scholar 

  85. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57–69

    Article  PubMed  CAS  Google Scholar 

  86. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43–55

    Article  PubMed  CAS  Google Scholar 

  87. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994; 12: 141–79

    Article  PubMed  CAS  Google Scholar 

  88. Crespo J, Cayon A, Fernadez-Gil P, et al. Gene expression of TNF-α and TNF receptors, p55 and p 75. J Hepatol 2001; 34: 1158–63

    Article  CAS  Google Scholar 

  89. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57–65

    PubMed  CAS  Google Scholar 

  90. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557–62

    Article  PubMed  CAS  Google Scholar 

  91. Yang S, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidative stress. Arch Biochem Biophys 2000; 378: 259–68

    Article  PubMed  CAS  Google Scholar 

  92. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417–26

    Article  PubMed  CAS  Google Scholar 

  93. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of UCP-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692–700

    Article  PubMed  CAS  Google Scholar 

  94. Baffy G, Zhang C-Y, Glickman JN, et al. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002; 35: 753–61

    Article  PubMed  CAS  Google Scholar 

  95. Cortez-Pinto H, Chatham J, Chacko V, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659–64

    Article  PubMed  CAS  Google Scholar 

  96. Diehl AM. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1–5

    PubMed  CAS  Google Scholar 

  97. Li Z, Lin H, Yang S, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002; 123: 1304–10

    Article  PubMed  CAS  Google Scholar 

  98. Matsui K, Yoshimoto T, Tsutsui H, et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997; 159: 97–106

    PubMed  CAS  Google Scholar 

  99. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828–33

    Article  PubMed  CAS  Google Scholar 

  100. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297–306

    Article  PubMed  CAS  Google Scholar 

  101. Nieto N, Friedman SL, Greenwel P, et al. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999; 30: 987–96

    Article  PubMed  CAS  Google Scholar 

  102. Svegliati-Baroni G, Saccomanno S, van Goor H, et al. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001; 21: 1–12

    Article  PubMed  CAS  Google Scholar 

  103. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129–40

    Article  PubMed  CAS  Google Scholar 

  104. Leclercq IA, Farrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206–13

    Article  PubMed  CAS  Google Scholar 

  105. Saxena NK, Ikeda K, Rockey DC, et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762–71

    Article  PubMed  CAS  Google Scholar 

  106. Ikejima K, Yoshiyuki T, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399–410

    Article  PubMed  CAS  Google Scholar 

  107. Ueno T, Sagawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103–7

    Article  PubMed  CAS  Google Scholar 

  108. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829–34

    Article  PubMed  CAS  Google Scholar 

  109. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408–13

    PubMed  CAS  Google Scholar 

  110. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98: 926–30

    Article  PubMed  CAS  Google Scholar 

  111. Harrison SA, Fincke C, Helinski D, et al. Orlistat treatment in obese, non-alcoholic patients: a pilot study [abstract]. Hepatology 2002; 36: 406A

    Google Scholar 

  112. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519–25

    Article  PubMed  CAS  Google Scholar 

  113. Neuschwander-Tetri BA, Brunt EM, Bacon BR. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPAR agonist rosiglitazone [abstract]. Hepatology 2002; 36: 379A

    Google Scholar 

  114. Nair S, Diehl AM, Perrillo R. Metformin in non alcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report [abstract]. Gastroenterology 2002; 1222: A621

    Google Scholar 

  115. Marchesini G, Brizi M, Blanchi G, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893–4

    Article  PubMed  CAS  Google Scholar 

  116. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis [abstract]. Gastroenterology 2002; 122: A669

    Google Scholar 

  117. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667–72

    Article  PubMed  CAS  Google Scholar 

  118. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711–7

    Article  PubMed  CAS  Google Scholar 

  119. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter]. J Hepatol 1999; 31: 384

    Article  PubMed  CAS  Google Scholar 

  120. Laurin J, Lindor KD, Crippen JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464–7

    Article  PubMed  CAS  Google Scholar 

  121. Horlander JC, Kwo PY, Cummings OW. Atorvastatin for the treatment of NASH [abstract]. Gastroenterology 2001; 120: A544

    Google Scholar 

  122. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [abstract]. Hepatology 1998; 28: 386A

    Google Scholar 

  123. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial [abstract]. Hepatology 1997; 26: 387A

    Article  Google Scholar 

  124. Desai TK. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [abstract]. Gastroenterology 2000; 118: A1071

    Google Scholar 

  125. Nitecki J, Jackson FW, Allen ML, et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [abstract]. Gastroenterology 2000; 118: A6679

    Article  Google Scholar 

  126. Lin HZ, Yang S, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998–1003

    Article  PubMed  CAS  Google Scholar 

  127. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198–208

    Article  PubMed  CAS  Google Scholar 

  128. Anderson T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991; 12: 224–9

    Article  Google Scholar 

  129. Despres J-P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716–20

    Article  PubMed  CAS  Google Scholar 

  130. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270–9

    Article  PubMed  CAS  Google Scholar 

  131. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-acitivated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953–6

    Article  PubMed  CAS  Google Scholar 

  132. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797–802

    Article  PubMed  CAS  Google Scholar 

  133. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226–32

    Article  PubMed  CAS  Google Scholar 

  134. Kim Y-B, Ciaraldi TP, Kong A, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110 protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51: 443–8

    Article  PubMed  CAS  Google Scholar 

  135. Galli A, Crabb DW, Cerri E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924–40

    Article  PubMed  CAS  Google Scholar 

  136. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074–81

    Article  PubMed  CAS  Google Scholar 

  137. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74

    PubMed  CAS  Google Scholar 

  138. Lu SC. S-adenosylmethionine. Int J Biochem Cell Biol 2000; 32: 391–5

    Article  PubMed  CAS  Google Scholar 

  139. Mato JM, Camara J, Ortiz P, et al. Spanish collaborative group for the study of alcoholic liver cirrhosis. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind mutlicentre clinical trial. J Hepatol 1999; 30: 1081–9

    CAS  Google Scholar 

  140. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by an AASLD/Schering Advanced Hepatology Fellowship grant. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, Missouri, 63110, USA

    Stephen A. Harrison &  Adrian M. Di Bisceglie

Authors
  1. Stephen A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian M. Di Bisceglie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian M. Di Bisceglie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, S.A., Di Bisceglie, A.M. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease. Drugs 63, 2379–2394 (2003). https://doi.org/10.2165/00003495-200363220-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363220-00001

Keywords

Search

Navigation